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Abstract
Hepatitis C is a pandemic human RNA virus, which commonly causes chronic infection and liver disease. The
characterization of viral populations that successfully initiate infection, and also those that drive progression to chronicity is
instrumental for understanding pathogenesis and vaccine design. A comprehensive and longitudinal analysis of the viral
population was conducted in four subjects followed from very early acute infection to resolution of disease outcome. By
means of next generation sequencing (NGS) and standard cloning/Sanger sequencing, genetic diversity and viral variants
were quantified over the course of the infection at frequencies as low as 0.1%. Phylogenetic analysis of reassembled viral
variants revealed acute infection was dominated by two sequential bottleneck events, irrespective of subsequent chronicity
or clearance. The first bottleneck was associated with transmission, with one to two viral variants successfully establishing
infection. The second occurred approximately 100 days post-infection, and was characterized by a decline in viral diversity.
In the two subjects who developed chronic infection, this second bottleneck was followed by the emergence of a new viral
population, which evolved from the founder variants via a selective sweep with fixation in a small number of mutated sites.
The diversity at sites with non-synonymous mutation was higher in predicted cytotoxic T cell epitopes, suggesting immune-
driven evolution. These results provide the first detailed analysis of early within-host evolution of HCV, indicating strong
selective forces limit viral evolution in the acute phase of infection.
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Introduction
Hepatitis C virus (HCV) infection is a major cause of chronic
liver disease, resulting in substantial morbidity and mortality
worldwide, with between 123 and 170 million persons infected [1].
Transmission is predominantly via blood-to-blood contact associ-
ated with contaminated injection devices. Infection persists in
approximately 70% of acute cases, leading to chronic hepatitis,
and ultimately cirrhosis and the associated complications of liver
failure and hepatocellular carcinoma [2]. The outcome of primary
HCV infection is driven by the interplay between rapid viral
evolution and host adaptive immune responses [3,4]. Analogous to
other RNA virus infections, development of effective vaccines and
antiviral treatments has been constrained by the ability of these
viruses to swiftly overcome evolutionary pressures such as host
immunity and antiviral drugs [5–7].
The rapid rate of evolution in RNA viruses is driven by a highly
error-prone RNA-dependent RNA polymerase (RdRp). For HCV,
the estimated mutation rate is 1.2610
24 substitutions per site per
infected cell [8], and with a half-life of 3–5 hrs, it is estimated that
at least 10
12 particles are generated per day [9]. With these rapid
kinetics, at least 10
9 variants with single- and double-nucleotide
changes are likely to arise in each individual multiple times daily
[10]. However, the observed viral complexity is much less than this
prediction, largely due to reduced fitness of mutated variants [11].
While the error-prone viral replicase results in a continuous supply
of new viral variants (genetic drift), purifying selection generated
from host immune pressure and viral fitness results in culling and
preferential selection of certain variants. When selection overbal-
ances drift, a genetic bottleneck occurs (i.e. evolutionary events
resulting in a reduction in genetic variation due to extinction of a
significant proportion of the viral variants).
Very little quantification of the within-host evolutionary
dynamics of human RNA viruses has been reported, and limited
information exists from experimental evolution systems [12], and
from viruses infecting animals. For RNA viruses, the effective
population size - broadly equated with the number of variants that
will contribute genes to the next generation, a key parameter in
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often seen at the epidemiological level as result of a strong
transmission bottleneck. Well-characterized within-host genetic
bottlenecks have been observed upon transmission of a number of
RNA viruses, including HIV [13–15]. A low effective population
size has important consequences for viral evolution, as at small
effective population numbers (Ne), random processes (i.e. genetic
drift) predominate over deterministic ones (i.e. selection) [16].
Genetic bottlenecks severely limit viral diversity and potentially
limit replicative fitness of the resultant virus (reviewed in [12]).
After a bottleneck event, RNA viruses undergo rapid evolution,
leading to accumulation of deleterious mutations and the
occurrence of rare fit variants, which can rapidly reach fixation
and dominate the next population.
Following a genetic bottleneck, within-host evolution of rapidly
mutating viruses can be characterized by selective sweeps (i.e. the
reduction or elimination of variants in the viral population as the
result of strong selection pressures), with only a few variants
emerging to dominate the future population. This phenomenon is
common at the host population level, such as in influenza [17],
and has been documented within-host for HCV [18,19] and HIV
[20]. The extent to which positive selection and random genetic
drift contribute to the within-host evolution of HCV, and whether
selective sweeps observed late in primary infection are related to
genetic bottleneck events, remain to be resolved.
A major challenge in studies of the within-host evolution of
RNA viruses lies in the capacity to detect low frequency viral
variants. Standard cloning techniques, and more recently single
genome amplification, followed by sequencing have been used to
detect variants present at frequencies as low as 10–15%
[15,21,22]. Next generation sequencing (NGS), despite high
technical errors [23], allows detection of rare variants present at
less than 1% of the population [24–33]. Data analysis tools have
now improved the ability to differentiate true biological variation
from technical error [34,35], and also enabled reconstruction of
genomic regions of individual variants from short NGS reads
[34,36].
The early evolution of HCV has been investigated to date only in
limited case series [18,30,35,37–40], and with a strong bias towards
symptomatic cases, who represent a small minority of those with
acute infection, and who are known to have an increased likelihood
of clearance [3,4]. Few studies have investigated early infection in a
longitudinal fashion [30,35,39,41]. In these cases the frequency,
distribution, and timing of viral mutations has been characterized
only in limited regions of the virus and with low sensitivity in the
detection of rare variants.
Here we report a comprehensive analysis of longitudinal
collected samples from four subjects identified very early in
asymptomatic acute HCV infection. The aim was to quantify the
number of successfully transmitted founder viruses, and to
characterize the diversity and complexity of viral population
across the genome over the course of the primary infection leading
to clearance or chronicity.
Results
Subjects
Four newly viremic seronegative subjects were studied (Figure 1,
Table 1, Table S1). Subjects were enrolled in the Hepatitis C
Incidence and Transmission Study (HITS) cohort, and had tested
negative for HCV antibodies and RNA within 3–6 months prior
[42,43]. The estimated days post-infection (DPI) at enrolment
ranged from 30–45 days (Table 1). Two subjects cleared the
infection (686_Cl, 360_Cl), and the other two progressed to
chronic infection (23_Ch, 240_Ch). A single viral genotype (GT)
was detected in each subject: two with GT1a (686_Cl, and
23_Ch), and two with GT3a (360_Cl, and 240_Ch). Figure 1
shows the HCV RNA levels and HCV-specific IgG antibody titers
(estimated as the optical density to cut-off ratio in the enzyme
immunoassay) over the course of infection.
For the purposes of this analysis, the time course of the primary
infection was divided into three phases: i) transmission; ii) an acute
phase (designated as ,100 DPI); and iii) a pre-chronic phase
(designated as .100 DPI) leading to clearance or chronicity at six
months post-infection).
Evolutionary dynamics of viral diversity over the course
of the infection
NGS, standard cloning and bulk (consensus) sequencing were
performed on viremic samples collected longitudinally from each
of the subjects (Figure 1). On average, 81,900 reads with average
read lengths of 358 bp were generated per subject per timepoint,
giving an average coverage depth of 3,093 (Table S2). Single
nucleotide polymorphisms (SNP) analysis revealed between 160
and 460 nucleotide substitutions per timepoint. Over the course of
the infection more than half of the substitution events occurred at
frequencies of ,1%, except in subject 240_Ch (38%). Non-
synonymous substitutions constituted 40%–57% of the total and
were distributed across the genome (Figure 2). Within the first 60
DPI, the prevalence of non-synonymous substitutions was
approximately half of the total (50–57%), except in subject
686_Cl (34%). Subject 686_Cl showed the highest prevalence of
substitutions with a frequency ,1% (76% during the first 60 DPI).
In the two subjects who became chronically infected (23_Ch and
240_Ch), the prevalence of substitutions was significantly higher
than in subjects who ultimately cleared the infection (686_Cl and
360_Cl). In subjects that progressed to chronicity, some substitu-
tions reached frequencies above 99% (i.e., fixations; see also
below).
Shannon entropy (SE) was calculated from the frequencies of
nucleotide substitutions measured across the genome. During the
Author Summary
Primary hepatitis C (HCV) infection is typically asymptom-
atic and commonly results in persistent infection. The
characteristics of early infection remain undefined. Four
subjects were studied longitudinally from within a few
weeks of transmission until resolution of outcome, via a
full genome analysis of viral evolution. In the acute phase
(,100 days post-infection) there were two periods with a
major reduction in genetic diversity (i.e. a bottleneck)
irrespective of subsequent clearance (n=2) or chronic
infection (n=2). The first bottleneck was associated with
transmission, with generally only one ‘founder’ virus
successfully establishing infection. The second occurred
following the primary peak in viraemia, concomitant with
seroconversion, approximately 100 days post-infection. In
the subjects who became chronically infected, the second
bottleneck was followed by emergence of a new cluster of
variants, which evolved from the founder(s), and carried
only a small number of mutated residues that reached
fixation. Some fixations occurred in known targets of CD8
cytotoxic T cell and neutralizing antibody responses. These
results indicate a common evolutionary pattern, indepen-
dent of disease outcome in the acute phase of HCV
infection, with strong signatures of selective pressures
driving the transition into chronic infection. These novel
data will inform preventative vaccine strategies.
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diversity. This decline did not follow the HCV RNA kinetics.
Similar patterns were observed for SE calculated with all
substitutions, or with only non-synonymous changes. In two
subjects (686_Cl, 23_Ch) at least two pre-seroconversion time-
points were sampled within a window of eight weeks, allowing an
accurate assessment of very early HCV evolution, and revealing a
peak in viral diversity in temporal proximity to the viremic peak.
In the two subjects who ultimately became chronically infected
(23_Ch and 240_Ch), SE increased in the pre-chronic phase, which
also featured a continued increase in HCV RNA level (Figure 1).
The observed patterns of change in SE measured across the full
genome were not consistently observed in the 10 protein-encoding
regions, clearly indicating a non-uniform evolution of HCV across
the genome and between subjects.
Transmission - First bottleneck
To test the hypothesis that a single virus establishes infection
upon transmission, a statistical model, PoissonFitter [44] was used
to examine whether the viral population had a star-like phylogeny
Figure 1. RNA level, Shannon entropy, and antibody titers over time for the four early infection subjects. Panels A and B show two
subjects who developed chronic infection (240_Ch, 23_Ch) followed from pre-seroconversion timepoints. Panels C and D show the infection
dynamics for two subjects who ultimately cleared the infection (360_Cl, 686_Cl). Red dots represent viremic time points analyzed via next generation
sequencing (NGS). The solid line represents the RNA level. The dashed and dotted lines represent the interpolation of the Shannon entropy calculated
across the genome at each time point using NGS data. Entropy was calculated using all mutated sites (dotted line), or with only non-synonymous
sites (dashed line). The shaded area represents semi-quantitative estimates of the anti-HCV antibody titer (OD: cut-off). Note the varied ranges in the
x- and y-axes.
doi:10.1371/journal.ppat.1002243.g001
Table 1. Subject characteristics, number of founder viruses, and estimates of the time since the most recent common ancestor
(tMRCA).
Subject
ID Sex
Disease
outcome GT Age
First sampling
timepoint
(DPI
a)
Observed
duration of
viraemia (DPI)
Timepoints
analysed via
NGS
b
Length of
genome
investigated
Maximum
entropy (full
genome
c)
Number of
founder
viruses
Poisson
estimated
tMRCA (95%
CI)
d
686_Cl F Cleared 1a 25 33 117 4 9172 0.010414 1 35 (26,47)
23_Ch M Chronic 1a 25 36 304 6 9138 0.002323 2 44 (24, 64)
360_Cl M Cleared 3a 29 30 223 2 5992 0.003190 1 34 (20, 57)
240_Ch M Chronic 3a 24 44 477 4 9226 0.001546 1 34 (19,48)
aEstimated days post-infection (DPI).
bNext Generation Sequencing.
cCalculated across the genome for non-synonymous substitutions.
dMean value from the estimates of the time since most recent common ancestor (tMRCA) estimated from reconstructed viral variants across the genome in windows of
400 nt calculated according to a Poisson model of viral mutation (45). Confidence intervals are the 5
th and 95
th percentiles of the total range of confidence intervals
estimated in each of the windows analyzed across the genome.
doi:10.1371/journal.ppat.1002243.t001
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viral variants were obtained from NGS reads using a Bayesian
statistical tool, ShoRAH [34,36]. Firstly, viral haplotypes were
reconstructed from NGS data at the first viremic timepoint
segregated into 400 nt windows across the genome (see Table S3,
including the number of variants reconstructed per window).
Secondly, reconstructed haplotypes of the E1/HVR1 (871 nt) and
partial E2 (932 nt) regions were utilized, along with the
corresponding E1/E2 clonal sequences (Table S3). In the second
dataset, only variants with a frequency greater than 2.5% were
included in this analysis. This cut-off was derived through a
validation analysis for the method of reconstruction of viral
haplotypes (of length . 400 nt) using a mixed sample of four
plasmid E1/E2 clones derived from one subject (see Supporting
Text S1 for details). By definition, the sequence of the founder was
identified as being: i) the most prevalent variant; and ii) identical to
the consensus sequence of the viral population at the first time
point [15,22].
Both the PoissonFitter tests and phylogenetic analyses indicated
that the HCV infection in three subjects (686_Cl, 360_Cl, and
240_Ch) was successfully established by a single variant (Figures 3,
S1, S2 and Table S3). For these subjects, the highlighter plots
show the random distribution of SNPs across the sequences, again
consistent with a star-like distribution of variants arising from a
single founder. By contrast, Poisson analysis of the remaining
subject (23_Ch) indicated that more than one virus established the
infection. Phylogenetic analyses of E1, E2 and NS3 regions of
subject 23_Ch indicated that at least two viruses had established
the infection, designated 23AF and 23BF (Figures 3 and S1, Table
S3). These founders generated two major clusters of variants,
which were named after the founder variants. These two founder
variants were identified with comparable prevalence in both E1/
HVR1 (Figure S1) and E2 regions (Figures 3). The average genetic
difference between these two dominant variants over E1/E2
regions was 1.3%. In support of these results, the founder variants
were also identified via clonal sequencing in both E1/HVR1
(Figure S1) and E2 regions (Figure 3). For 23_Ch, the calculation
of the exact number of founder viruses was confounded by the
presence of several variants that appeared to have arisen from
recombination events between two viruses from each cluster (see
for example, variant C1_14b in Figure 3).
A total of 2-5 variants (including the founders) were detected
with a frequency above 2.5% in 240_Ch, 686_Cl, and 360_Cl at
the first viremic timepoint. Subject 23_Ch presented the most
diverse repertoire, with nine variants present in the E1/E2 region.
These results, in combination with the fact that .50% of
substitutions were present at a frequency ,1% (see above),
indicate that early HCV evolution was characterized by a large
distribution of low frequency variants.
The time since the most recent common ancestor (tMRCA),
which is estimated with PoissonFitter, provides an empirical
measure of the likely timing of the transmission event [22,45]. The
estimated tMRCA from independent analyses of E1/HVR1 and
partial E2 regions closely matched the DPI estimated from the
Figure 2. Distribution of the non-synonymous substitutions detected across the genome over the course of the infection. Panels A
and B show the distributions of non-synonymous substitutions in two subjects who developed chronic infection (240_Ch, 23_Ch). Panels C and D
show two subjects who ultimately cleared the infection (360_Cl, 686_Cl). Each panel shows the longitudinal analysis of the distribution of non-
synonymous substitutions for each subject. In subjects who cleared the infection, substitutions sporadically emerged at low frequency (,50%). In the
two subjects that developed chronic infection, several substitutions across the full genome reached fixation (.99%). Colors represent the time course
post-infection (see legend).
doi:10.1371/journal.ppat.1002243.g002
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estimated from the founder analyses in windows of 400 nt across
the full genome also matched the DPI estimated from the
seroconversion timepoint (Table S3). As expected, estimates of the
tMRCA in 23_Ch from genomic regions with evidence of at least
two founders were longer than those estimated from the
seroconversion timepoint, indicating that the observed diversity
was not likely to be generated by a single founder.
Acute phase - Second bottleneck
Analysis of the viral dynamics in the acute phase of infection (i.e.
,100 DPI) for each subject revealed a second genetic bottleneck
event brought about by the extinction of several variants. Evidence
for this second bottleneck was supported by: i) the decline in SE for
all four subjects at the end of the acute phase; ii) a decline in viral
diversity evidenced by phylogenetic analysis; and iii) a decrease in
the effective population size estimated from viral sequences in the
two subjects who developed chronic infection.
Phylogenetic reconstruction of partial E2 nucleotide sequences
showed a decline in viral diversity at the end of the acute phase
(Figure 4). In 240_Ch, infection was successfully initiated with a
single founder, 240AF, identified here as the most prevalent
variant (85% of the population) of the cluster (termed 240AF after
the founder) observed in the acute phase (Figures 3 and 4). The
early increase in prevalence of the founder variant (up to 97% by
57 DPI) and the absence of minor viral variants, are consistent
with the observed decline in SE and increase in HCV RNA level.
The two founders identified in 23_Ch differed only at three
residues in the E2 region (402, 443 and 446). Initially, these
founders were present at comparable levels within the viral
population (26% and 16% respectively, Figure 4). However, by 60
DPI, the founder variant within cluster 23AF was undetectable -
concomitant with seroconversion and with the decline in HCV
RNA level between 44 DPI and 60 DPI (Figure 4). The prevalence
of the second founder variant, 23BF remained reasonably stable
within the cluster until 60 DPI, whereas by 74 DPI its frequency
was greatly diminished, consistent with the overall reduction in
HCV RNA level. Similar patterns of decline in viral diversity were
also observed by phylogenetic analyses in other regions of the same
subjects (E1/HVR1, Figure S3 and NS3, Figure S4) and also in
the other two subjects (not shown).
Figure 3. Founder virus analysis based on partial E2 region of the viral genome. Panels A and B show the analyses for two subjects who
developed chronic infection (240_Ch, 23_Ch) followed from pre-seroconversion timepoints. Panels C and D show the analysis for two subjects who
cleared the infection (360_Cl, 686_Cl). Phylogenetic reconstructions and highlighter plots are shown, illustrating the genetic relatedness between
HCV variant sequences. Names of each sequence are labeled with a letter (H for haplotype, and C for clone), with the first number representing the
sampling timepoint and with the second number representing either the prevalence of the haplotype or the clone number. The phylogenetic trees of
subjects 686_Cl, 360_Cl and 240_Ch (panels A, C, D) are consistent with an infection arising from a single founder. The fit with a Poisson model is also
consistent with a single founder (p-value . 0.1, see text). As shown by the highlighter plots, founder viruses are identified as the consensus sequence
and coincided with the most prevalent variant reconstructed from NGS data, (e.g. for subject 686_Cl H1_0.60 is identical to the consensus sequence
and to clone C_12b). The highlighter plots also show the random distribution of mutated sites with respect to the founder sequence (master), which
is consistent with a star-like phylogeny. The phylogenetic analysis in 23_Ch (panel B) is consistent with an infection originated from two founder
viruses (indicated with an asterisk in the highlighter plot) giving rise to two major clusters, 23A and 23B. This is consistent with the rejection of the
Poisson model (p-value=0). Phylogenetic trees were obtained using PhyML, with Maximum Likelihood methods using a GTR model of substitution as
suggested by model testing.
doi:10.1371/journal.ppat.1002243.g003
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amino acid level in the partial E2 region (Figure 5) and E1/HVR1
(data not shown), also showed the dominance of two distinct
viruses for 23_Ch (23AF and 23BF) and one for 240_Ch (240AF)i n
the acute phase. Minor variants emerged during this phase with the
majority receding below the limit of detection.
A decrease in the effective population size also provided
evidence of sequential bottleneck events. A coalescent demo-
graphic reconstruction of the viral population within each host,
using the Bayesian skyline plot [46] on E1/HVR1 and partial E2
regions (Figure 6) revealed a decline in diversity (measured as Nt,
the product of the effective population size and generation length
in days) during the acute phase of infection in both subjects who
became chronically infected (23_Ch and 240_Ch). The estimates
of the time of infection from this analysis were consistent with
those found via the Poisson model (Table S3). Demographic
reconstruction for subjects who cleared infection (360_Cl and
686_Cl) showed little variation in effective population size over the
course of the infection (Figure S5), which is likely to reflect the
short time interval covered by the available samples.
Pre-chronic phase - Selective sweep
The pre-chronic phase (i.e, .100 DPI) featured selective sweeps,
with the new variants arising from the preceding viral population
in the acute phase, showing remarkably few substitutions reaching
fixation in the new population. In subject 240_Ch, following the
decline in HCV RNA level at 140 DPI, a new cluster of variants,
termed here 240AC, figure 4) replaced the 240AF cluster via a
selective sweep brought about by the second bottleneck event.
Similarly, in 23_Ch, the recrudescence of viremia in the pre-chronic
phase was associated with the emergence of a new cluster, 23AC,
which evolved only from cluster 23AF via a selective sweep
(Figure 4b). In both subjects a single variant dominated the pre-
chronic phase population, accounting for 74% of the total HCV
RNA level in subject 23_Ch, and approximately 50% in 240_Ch.
Further evidence in support of the establishment of a new viral
Figure 4. Evolutionary dynamics of HCV variants over the partial E2 region of the genome. Sequence analyses of the two subjects who
developed chronic infection, 240_Ch (A), and 23_Ch (B) revealed the presence of selective sweeps. These sweeps led to the emergence of new
variants that replaced the founder viruses (identified with an asterisk). Phylogenetic trees (left panels in A and B) display nucleotide sequences of
reconstructed haplotypes derived from NGS data and clonal sequences. Names of each sequence are labeled with a letter (H for haplotype and C for
clone), with the first number representing the sampling timepoint and with the second number representing either the prevalence of the haplotype
or the clone number. Colors are also used to portray the sampling timepoint (see legend). Infection dynamics for subject 240_Ch are consistent with a
single founder, identified with the most prevalent strain of cluster 240A (H2_0.85 and H3_0.97 at time-points 2 and 3 respectively), with clone C2_6,
and with the consensus of the sequences from time-point 1. The pre-chronic phase (corresponding with the color-coded time ranges 5 and 6) of
infection shows the emergence and dominance of a new subgroup of viruses, designated 240B. 23_Ch has at least two founder viruses that
successfully initiated the infection (H1_0.26 and H1_0.16 within the two clusters 23AF and 23BF, respectively), A new cluster 23AC, termed after the
dominant variant H5_0.54, emerged in the pre-chronic phase and replaced cluster 23AF. Trees are calculated using Maximum Likelihood method
(implemented in PhyML).
doi:10.1371/journal.ppat.1002243.g004
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PLoS Pathogens | www.plospathogens.org 6 September 2011 | Volume 7 | Issue 9 | e1002243Figure 5. Evolution of the partial E2 region of individual HCV variants at the amino acid level. The plots in A (subject 240_Ch) and B
(23_Ch) show the dynamics of the individual viral variants over time. In 240_Ch, infection was initiated with one founder variant, 240AF, which was
then replaced sequentially by two related variants, 240AC1 and 240AC2, respectively. In 23_Ch, at least two founders initiated infection, 23AF and 23BF,
Viral Evolution in Hepatitis C Virus Infection
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effective population size following the second bottleneck, which
was particularly evident for 240_Ch (Figure 6).
Fixation (.99%) was observed in a limited number of sites in
association with the selective sweep (Figure 2). Fixation occurred at
two sites in 23_Ch by 136 DPI (E2, 542; NS3, 1498) and at 12 sites
in 240_Ch by 159 DPI (E1, 372; E2: 443, 483 and 543; NS2, 750;
NS3: 1509, 1606; NS4b: 1768; NS5a: 1985, 1999; NS5B: 2497
and 2973). Further evolution was observed with additional fixation
sites occurring by 304 DPI in NS2 (856) and NS5B (2629),
indicating the presence of a further selective sweep event. In
subject 240_Ch a further selective sweep event occurred by 477
DPI, with fixations observed in E2 (400, 405, 408, 583), NS3
(1641), and NS5a (2361).
Evidence of immune driven selection
In order to determine whether non-synonymous substitutions
were likely to be driven by cellular and humoral immune
responses, we identified the location of predicted, as well as
experimentally-verified, epitopes across the full genome for each
subject (Table S4). Analysis of HLA class I restricted cytotoxic T
cell (CTL) epitopes revealed a total of 62 amino acid substitutions
(29 in 23_Ch, 12 in 240_Ch, 8 in 686_Cl, and 13 in 360_Cl)
which were found to be located in HLA-restricted epitopes (Table
S4, Figure 5). Twenty-four of these substitutions resulted in mutant
epitopes with a lowered predicted binding score, suggesting that
these substitutions potentially conferred a CTL immune escape
phenotype (Table S5). In 23_Ch, all four sites that reached fixation
in the pre-chronic phase lay within HLA-restricted epitopes. In
240_Ch, of the 18 sites that reached fixation in the pre-chronic
phase, nine lay within CTL epitopes.
Figure 5 shows the location of the E2 mutations within putative
CTL and B cell epitopes in the different variants in subjects 23_Ch
and 240_Ch, as well as mutations previously shown to be
associated with viral fitness costs. All the identified epitopes within
this region carried at least one amino acid change. Two of these
mutations (G483D for 240_Ch and T542I for 23_Ch) generated
CTL epitopes with reduced binding affinity, thus indicating
potential immune escape (Table S4). Interestingly, both subjects
also showed a substitution at position 443 (Y443I for 23_Ch and
Y443H in 240_Ch) known to be within a B cell epitope [47]. In
240_Ch a mutation at 543 was observed (T543A). Mutations at
this site have been reported to alter the yield of precipitated E1/E2
proteins [48].
Comparison between SE (based on all substitutions) at sites of
predicted CTL epitopes, with sites at which no epitopes were
predicted, revealed significant differences for each subject (Mann
Whitney; all p,0.01). In three subjects (excluding 686_Cl who
had rare HLA-B alleles, and hence limited information available
for epitope prediction), the distribution of SE values based only on
non-synonymous substitutions, revealed that epitope regions
carried higher SE values (Mann Whitney; p,0.01). These results
which both dominated the early phase of infection before being replaced by a new variant in the pre-chronic phase of infection (23AC). The y-axis
shows the contribution of each variant with respect to the RNA level. Below each graph is an amino acid alignment indicating the distinguishing
residues for the different variants. The location of putative CTL (pink shading) and B cell (green shading) epitopes, and mutations with previously
recorded viral fitness costs (light blue shading) are indicated. All the identified epitopes within this region carried at least one amino acid change. Two
of these mutations (G483D for 240_Ch and T542I for 23_Ch) generated CTL epitopes with reduced binding CTL affinity, and both subjects showed a
substitution at position Y443, known to be within a B cell epitope [47] - all of which is suggestive of immune escape. In addition, in 240_Ch a
potential fitness cost associated mutation was observed at T543A [48].
doi:10.1371/journal.ppat.1002243.g005
Figure 6. Demographic reconstruction of the viral populations. Demographic reconstruction from E1/HVR1 (A,B) and E2 (C,D) sequences for
subjects who developed chronic infection, 23_Ch (A,C) and 240_Ch (B,D). In both subjects, and in both genomic regions, the founder effect and
sequential bottleneck events are evident. The estimated effective population size (Nt, the product of the effective population size and generation
length in days) had a peak value of the order of 10
3, and then decreased to values of the order of 10
2. The longer estimate of tMRCA for 23_Ch when
compared to those in Table 1 is likely to be due to the presence of two founder viruses in this subject.
doi:10.1371/journal.ppat.1002243.g006
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cellular immune response, as has been shown in chronic infection
[49–52].
Discussion
This comprehensive examination of the pattern and kinetics of
viral evolution across the HCV genome has revealed that early
primary HCV infection features at least two significant genetic
bottleneck events. The first occurred during or immediately after
transmission, where only one or two founder viruses successfully
initiated infection. The second occurred within 100 DPI,
preceding a decline in HCV RNA level, and in temporal
proximity to seroconversion. This second bottleneck was followed
either by clearance, or by a selective sweep with new variants
emerging from the founder virus to dominate the pre-chronic phase
of infection. These quantitative analyses of early events in primary
HCV infection suggest that strong selective pressures limit viral
evolution both during transmission and early infection.
The demonstration here of a single founder virus in three of four
IDU-transmitted HCV cases is comparable to studies in HIV,
which have shown that the majority of subjects with mucosal
transmission had a single founder virus [14,15,22,53,54]. Inter-
estingly, HIV transmission via IDU was more commonly
associated with multiple viruses, although still less than five
founders [14]. Investigation of HIV Envelope sequences in 20
heterosexual transmission pairs revealed that the founder variant
in the recipient comprised only a small fraction of the viral variants
in the donor (i.e. ,5%) [55]. The only previous study in HCV
using NGS for founder analysis revealed that a small inoculum
could explain the limited diversity observed in early infection in
two genomic structural regions [30]. For both HIV and HCV, it
remains unclear whether the transmission bottleneck is attribut-
able to a low number of variants being transferred between hosts,
or is the result of early evolutionary events where a larger number
of strains are rapidly eliminated due to varying fitness constraints.
As the two founders identified in subject 23_Ch showed relatively
limited diversification from each other, it is also plausible that a
single founder underwent very rapid evolution within the first few
days post-infection in this case.
Very little is known about the phenotypic characteristics of
founder viruses in HCV. The Envelope sequences of founder
viruses in HIV consistently predict CCR5 tropism, concordant
with the evidence for utilization of this co-receptor for infection of
tissue macrophages and dendritic cells in the mucosa [56]. A
recent phenotypic analysis of HCV variants emerging in HCV-
infected liver transplant recipients indicated that strains with
increased viral entry efficiency and lower neutralizing affinity were
preferentially selected in the post-transplant phase [57]. In the
present study, one of the subjects (23_Ch) was infected with at least
two founder viruses that differed at only three sites within the
envelope region. Interestingly, residues 443 and 446 lie within, or
in close proximity to, one of the major CD81 binding domains,
spanning residues 436 – 443 [58], suggesting that founder variant
23BF may have had better infectivity allowing it to out-compete
variant 23AF in the acute phase. Phenotypic analysis of these two
variants is currently underway. On close analysis of some of the
minor variants within subject 23_Ch, evidence of potential
recombination was identified between the two founder variants.
Recombination has been described in RNA viruses, but with
limited evidence in HCV (reviewed in [59]). However, as these
putative recombinant strains are closely related, it is difficult to
distinguish a recombination event from convergent evolution,
where closely related variants incorporate common mutations due
to shared selective pressure [60]. Furthermore, PCR amplification
could also cause recombinant artefacts via template switching.
The novel finding of a genetic bottleneck occurring in the acute
phase in all subjects regardless of outcome, calls for comprehensive
investigation of the determinants of this phenomenon to identify key
factors driving HCV evolution towards chronicity. Consistent with
the results of this study, an early reduction in viral diversity within
the Envelope region was observed during the acute phase in subjects
who subsequently resolved primary HCV infection [19]. This result
is somewhat in contrast with the patterns of viral diversity reported
by Wang and colleagues who analysed the Envelope region using
NGSin three subjectswithsymptomaticHCVinfection [30]. These
authors concluded that there was limited diversification in the early
phase of infection, which then increased during the chronic phase.
However, this conclusion was derived from analysis of a limited
region of the genome, and with only one subject sampled
longitudinally in the acute phase (assuming a median interval of 50
days between infection and symptom onset). Also, quantification of
viral variants was performed only on two short segments of 200 nt
and with limited NGS coverage.
The sequential bottleneck events followed by selective sweeps
reported here highlights the complex population structure of
HCV, and the significance of evolutionary dynamics occurring
early in the infection, namely in the first few weeks post-infection.
A thorough analysis of these dynamics will ultimately guide
understanding of the mechanisms driving establishment of chronic
infection. The within-host evolution of HCV observed here is
consistent with at least two evolutionary models. Firstly, the
observed low effective population size may be the result of strong
constraints on infectivity, where only a few viruses can establish
infection at each generation. Alternatively, the observed temporal
changes in genetic diversity are consistent with a model of
evolution via sequential selective sweeps where strong immune
pressures drive the establishment of a few escape variants, which
then dominate the viral population surviving the bottleneck event.
This model has been proposed to explain the epidemiological
dynamics occurring in influenza infections [17].
The rapid fixations observed in this study suggest the presence
of selective pressures acting on the virus in early infection. The
mean number of generations required for a fixation to occur in a
neutrally-evolving haploid population (as in RNA viruses) is twice
the effective population size, 2 Neff (55). In the case of HCV, using
an approximate estimate of Neff=2000 derived from this study,
and a generation time of (say) four days, the estimated fixation
time is of the order of years. One explanation for the high fixation
rate is that escape from the immune system is likely to be a major
driver for such mutations, as well as the occurrence of
compensatory mutations. However, the fact that a second genetic
bottleneck occurred in the acute phase of the infection suggests that
chronic infection may not only be the result of escape from host
immune responses, but stochastic events may also be relevant,
such as genetic drift. In this scenario, strains surviving the second
bottleneck may not be those that escaped the immune response,
but merely random survivors [reviewed in 16].
A striking finding in the data presented here is that despite the
high mutation rate of HCV [8], the large number of infected
hepatocytes [61,62], and the rapid turnover of virions [9], the
observed number of substitutions, and of viral variants, during
early infection was relatively small, with the majority of
substitutions occurring at frequencies below 2%. In the present
study up to 60 variants were observed in the HCV Envelope from
viral samples at the first available timepoint (Table S3) and up to
100 variants from pre-chronic samples. These estimates are
consistent with those of Wang and colleagues, however, these
Viral Evolution in Hepatitis C Virus Infection
PLoS Pathogens | www.plospathogens.org 9 September 2011 | Volume 7 | Issue 9 | e1002243authors reported only up to four variants in the acute phase, and up
to 100 variants from viruses sampled 200 weeks post-infection
[30]. It is therefore conceivable that there may be a larger
population of variants hidden below the detection threshold in this
analysis (0.1%). Studies of HIV diversity have shown that up to 50
amino acid variants are detected in analyses of small epitope
regions [54], and at least 15–20 variants have been detected across
the full genome [22]. Given that HCV mutates faster than HIV
[8], these data raise the question as to why the observed diversity
in early HCV is comparable to, or less than, the diversity
measured in HIV. Two explanations are possible: firstly, HCV
may have an intrinsically higher fitness cost associated with
mutations – in another RNA virus, vesicular stomatitis virus,
approximately 40% of mutations have been reported to be
associated with extinction [8]. One potential instance of relevance
identified in the dataset reported here, was in subject 240_Ch,
where a CTL epitope in NS3 (surrounding residue 399T) mutated
towards I with increasing frequency over the first two timepoints
before disappearing below detection. Mutations at this site have
been reported to affect viral production [63] (Table S4). A second
potential explanation is that early HCV diversity is significantly
higher than in subjects with early HIV, but the prevalence of the
majority of variants is below the detection threshold – such a
skewed distribution has been reported for foot-and-mouth disease
virus using NGS [33].
In conclusion, this analysis suggests that the early phase of HCV
infection is characterized by strong sequential bottleneck events
where diversity is markedly reduced. Whether this is due to strong
selective pressure from the host immune response and/or viral
fitness cost, remains to be experimentally determined. However,
these data suggest that strong selective pressures limit viral
evolution early in infection both in subjects that clear infection
and those that progress to chronicity. Ultimately, better-informed
strategies to modify these selective pressures may alter this
outcome, potentially including immunotherapeutic approaches
via vaccination, or antiviral therapies to constrain viral replication
and hence escape.
Materials and Methods
HCV cohort
Four early incident cases were recruited from HITS, which is a
prospective cohort of HCV seronegative and HCV RNA negative
prison inmates in New South Wales, Australia [42]. Blood samples
were collected frequently over 24 weeks following initial viremia,
with at least one pre-seroconversion sample collected for each
subject (Table S1). HCV antibody testing was performed as
described [42]. The date of infection was estimated by subtracting
the average pre-seronversion window period, which has been
estimated at 51 days [64–66], from the midpoint between last
seronegative and first seropositive timepoints.
HCV antibody testing was performed using the qualitative
Abbott ARCHITECT anti-HCV chemiluminescent microparticle
immunoassay (Abbott Diagnostics, Abbott Park, IL, USA).
Qualitative HCV RNA detection was performed either using the
VERSANT HCV RNA Qualitative Transcription Mediated
Amplification (TMA) assay (Bayer Diagnostics, Emeryville, CA,
USA; lower limit of detection: 3,200 copies/ml) or COBAS
AmpliPrep/COBAS TaqMan HCV assay (Roche, Branchburg,
NJ, USA; lower limit of detection 223 genome copies/ml).
Ethics statement
Ethical approvals were obtained from Human Research Ethics
Committees of Justice Health (reference number GEN 31/05),
New South Wales Department of Corrective Services (reference
number 05/0884), and the University of New South Wales
(reference numbers 05094, 08081), all located in Sydney,
Australia. Written informed consent was obtained from the
participants.
RNA extraction and amplification of partial 59UTR to 39
NS5B for NGS
Viral RNA was extracted as previously described [67]. Near full
length HCV cDNA was synthesized from 8 ml of viral RNA with
the Superscript III First-Strand Synthesis System for RT-PCR
(Invitrogen, Mt. Waverley, Australia) and a genotype specific
primer (Table S6) according to manufacturers’ instructions. The
region spanning nt 98 to 9314 (nt position designated according to
H77, GenBank accession number AF011751) was amplified from
the cDNA in two (59 UTR - 39 NS2 and 39 NS2 - 39 NS5B) or
three fragments (59 UTR -39 NS2, 39 NS2 - 59 NS4B, and 59
NS4B - 39 NS5B) with genotype specific primers (Table S6) in a
single PCR round with SequalPrep Long PCR kit (Invitrogen).
First round PCRs were performed using 5 ml of cDNA added to
15 ml of PCR reaction mix according to manufacturers’ instruc-
tions (Invitrogen). First round PCR was carried out for 94uC for 2
min, then 10 cycles of 94uC, 50uC, 68uC for 30 sec, 30 sec and
6 min, respectively and followed with an additional 25 cycles of
94uC, 58uC, 52uC for 30 sec, 30 sec and 6 min (plus 20 sec extra
each cycle), respectively. Second round PCR was performed using
5 ml of first round product and an inner set of genotype specific
primers (Table S6) added to 45 ml of PCR reaction mix. Reaction
mix and conditions were as described above with one exception;
the annealing temperature was raised to 60uC.
For the GT3, and some GT1a samples (subject 686 2/3/09,
23/3/09 and 6/4/09, and subject 23 2/6/09, 2/7/09 and 1/9/
09), it was not possible to obtain a single amplicon spanning the 39
NS2 to 39 NS5B and this region was amplified from the first round
product in two fragments, 39 NS2 to 59 NS4B and 59 NS4B to 39
NS5B. Nested round amplification was performed with Platinum
Taq High Fidelity (Invitrogen). Reaction conditions were as
specified in the manufacturers’ instructions with 5 ml of first round
product added as template.
PCR products were electrophoresed on 0.8% agarose in 0.56
TBE buffer and products of the correct size were gel purified with
the QIAquick gel extraction kit (Qiagen) and confirmed to be the
amplicon of interest by direct sequencing on an ABI 3730 DNA
Analyzer (Applied Biosystems, Foster City, CA, US) using dye-
terminator chemistry.
Roche 454 FLX sequencing
PCR amplicons were quantified with the Picogreen dsDNA
assay (Invitrogen). Genome fragments amplified from the same
timepoint were pooled in equimolar amounts to obtain equal
coverage, and submitted for library preparation before subsequent
NGS [23] using 454 Roche FLX Titanium at the Murdoch
University, Perth, Australia. Pyrosequencing was performed in
three independent runs. The first two runs were carried out
without bar-coding. The last run was performed using bar-coding
given the improvement of this technology over the course of the
study. The last run included two samples for each of the subjects
23_Ch, 686_Cl, and 360_Cl. All other samples were analyzed in
the first two runs.
E1/E2 clones
The 39 end of Core to 59 end of p7 region was amplified for
selected timepoints from each subject with genotype specific
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Fidelity, using the gel purified PCR product submitted for deep
sequencing as the DNA template. The 2534 bp product was TA
ligated into the pGEM-T Easy vector (Promega, Wisconsin,
United States). Individual colonies were screened by PCR for
inserts of the appropriate size with vector specific primers and the
amplicons sequenced.
454 FLX data alignment
454 FLX sequence reads were removed prior to the assembly
stage if they were: shorter than 55 bp and had an average quality
score ,20. The terminal 20 nt were removed from all remaining
reads. These remaining sequences were aligned with a nucleotide
identity threshold of 95% against each subject’s unique consensus
sequencewiththealignmenttool,MOSAIK(http://bioinformatics.
bc.edu/marthlab/Mosaik). The recommended parameters for 454
data were used in aligning these reads. Each subject’s consensus
sequence was derived from sequencing the gel purified PCR
products on the ABI 3730 DNA Analyzer spanning the near full-
length genome generated at the first viremic timepoint. The quality
of the aligned file was assessed and reads were excluded from the
alignment on the following basis: i) hypermutated sequence
(sequences with more than 5 nt mutations within the first 20
position of the read in either of the ends; ii) reads with indels that
resulted in a frame-shift or reads with a high frequency (5%) of
indels relative to the reference.
SNP detection and haplotype reconstruction
Aligned 454 reads were further analyzed with a Bayesian
probabilistic method implemented in the software package
ShoRAH [68,69]. This software was used to: i) perform error
correction on 454 FLX reads; ii) estimate the distribution of SNPs
and their prevalence, using a detection threshold of 0.1%; iii)
reconstruct HCV variants (haplotypes) in local windows of 400 nt;
iv) reconstruct HCV haplotypes on the Envelope region of the
HCV genome (,1000 nt in length); and v) to estimate the
frequency of occurrence of reconstructed variants within the
sample. The result of this global analysis on the Envelope region
was compared to the available sequences obtained from standard
cloning and sequencing. The ShoRAH analyses were performed
in triplicate for each dataset to ensure that the stochastic nature of
Bayesian statistics based on Monte Carlo Markov Chain
simulations was not affecting the results. Only SNPs and variants
detected in all the three simulation runs were considered for
further analyses.
Further automated cleaning of the SNPs generated via the
ShoRAH method was performed, based on the following criteria:
(i) sequences where the reverse and forward strand differed in a
frequent base substitution, allowing only a difference of 10%
between forward and reverse reads; (ii) SNPs which were only
present at the end of reads; and (iii) if the nucleotides adjacent to
the SNP were part of a homopolymeric stretch. The results from
ShoRAH were also compared to those obtained using a cut-off
method, such as that provided in the software package, Varscan
[70].
For the analysis of the Envelope region of the genome, only
reconstructed variants with frequencies .2.5% were considered
for further analysis (see Supporting Text S1). The probabilistic
nature of the clustering algorithm allows for estimation of the
reliability of predictions. In the Bayesian scenario implemented in
ShoRAH, the fraction of iterations in which a haplotype is
reported estimates the posterior probability of the existence of that
haplotype. This posterior probability provides a confidence level
for the haplotype. Only haplotypes with confidence values
(posterior probabilities) greater than 0.9 are reported. Scripts
and parameter values used for the analyses are available upon
request. Parameters of ShoRAH have been chosen through a
detailed preliminary analysis on the sensitivity of these parameters
in collaboration with Dr Zagordi (personal communication).
Founder virus analysis
PoissonFitter was used to test the hypothesis that a single virus
establishes infection [71]. PoissonFitter performs two tests: one test
is based on the fit of the Poisson model to the frequency
distribution of the Hamming distance observed in each sample;
the other is a topological test to verify that observed frequencies
are distributed according to a star-like phylogeny (for this test, no
formal statistic is available and consequently no p-value is
obtained). In this model the main assumption is that a single
founder virus evolves under neutral evolution, generating a star-
like phylogeny, with a distribution of mutations conforming to a
Poisson distribution [15,45]. This means that early selective
pressures compromise the statistical analysis. For this reason, only
HCV sequences obtained from the first available viremic time
point for each subject were included in the founder virus analysis.
PoissonFitter test was performed on reconstructed viral variants in
E1/E2 region of the genome, as well as on reconstructed variants
obtained from 400 nt windows sliding across the full genome. A
type 1 error threshold a=0.01 was assumed to conclude whether
the Poisson test was rejected. For the initial analysis, in each
window a conclusion was made whether one, or more than one,
founder virus explained the observations. In cases where the two
tests described above were discordant (i.e. a significant fit with
Poisson test of a single founder virus, but no star-like phylogeny –
which occurred in seven analyses; or the Poisson test suggested
more than one founder while the topological test conformed to a
star-like phylogeny – which occurred in eight analyses) then early
stochastic events were assumed to have occurred, which limited
the validity of the tests. These early events could result from an
early selective pressure, or strong fitness advantage associated with
early mutations. In this analysis, the mutation rate for the HCV
genome was set to 1.2610
24, as recently estimated [72]. We
assumed the same value was constant across the HCV genome.
Phylogenetic analysis
Sequences from standard cloning and reconstructed haplotypes
were visualized and curated with MEGA [73] and R packages.
Phylogenetic and evolutionary analyses were performed with
PhyML [74]. Trees were constructed from sequences using a GTR
substitution model with gamma invariant sites, as suggested by
analyses using ModelTEST [75]. Trees were visualized with
FigTree. Estimates of tMRCA were performed with PoissonFitter
and with BEAST [76].
Demographic reconstruction of the within-subject viral popu-
lation was performed with skyline plots implemented in BEAST
[47,63]. The analysis was performed using both a strict clock
model and a relaxed molecular clock model. The length of the
MCMC chain was chosen so that the effective sample size (ESS)
for each parameter was . 100. Bayesian factors were then used to
decide the best model. For each subject, the null hypothesis of a
strict clock was not rejected according to the Bayes Factor
calculated from the posterior distributions obtained from each
model (BF,2).
The evolutionary distances were estimated as within-group
mean genetic distances estimated using Maximum Composite
Likelihood (implemented in Mega 5) from reconstructed variants
from NGS in the E1/E2 region of the HCV genome.
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Subjects were HLA typed (Table S2) and MHC Class I
restricted epitopes were predicted using available algorithms in
http://www.immuneepitope.org. For each subject, several differ-
ent algorithms were tested with similar results. For simplicity, the
results presented are derived from prediction with NetMHC
http://www.cbs.dtu.dk/services/NetMHC/, which uses an artifi-
cial neural network for predictions. Known HCV epitopes were
retrieved from the database http://www.immuneepitope.org (last
access, 24 January 2011).
Predicted HLA-A or B restricted epitopes derived from
consensus sequence of the viral genome at each time point and
in each subject, were used to test the hypothesis that the
distribution of Shannon entropy measures in genomic regions
carrying predicted epitopes differ from the distribution of Shannon
entropy values in region without predicted epitopes. Statistical
testing was performed using the Mann-Whitney U test. A one-
tailed test was performed to examine the hypothesis that epitope
regions had higher SE measures than non-epitope regions.
Supporting Information
Figure S1 Founder virus analysis based on E1/HVR1 of
the viral genome. Panels A and B show the analyses for two
subjects who developed chronic infection (240_Ch, 23_Ch)
followed from pre-seroconversion timepoints. Panels C and D
show the analysis for two subjects who cleared the infection
(360_Cl, 686_Cl). Phylogenetic reconstructions and highlighter
plots are shown, illustrating the genetic relatedness between HCV
variant sequences. Names of each sequence are labeled with a
letter (H for haplotype, and C for clone), with the first number
representing the sampling timepoint and with the second number
representing either the prevalence of the haplotype or the clone
number. The phylogenetic trees of subjects 686_Cl, 360_Cl and
240_Ch (panels A, C, D) are consistent with an infection arising
from a single founder. The fit with a Poisson model is also
consistent with a single founder (p-value . 0.1, see text). As shown
by the highlighter plots, founder viruses are identified as the
consensus sequence and coincided with the most prevalent variant
reconstructed from NGS data, (e.g. for subject 686_Cl H1_0.70 is
identical to the consensus sequence and to six clone sequences, see
Highlighter plot). The highlighter plots also show the random
distribution of mutated sites with respect to the founder sequence
(master), which is consistent with a star-like phylogeny. The
phylogenetic analysis in 23_Ch (panel B) is consistent with an
infection originated from two founder viruses (indicated with an
asterisk in the highlighter plot) giving rise to two major clusters,
23AF and 23BF. This is consistent with the rejection of the Poisson
model (p-value=0). Phylogenetic trees were obtained using
PhyML, with Maximum Likelihood methods using a GTR model
of substitution as suggested by model testing.
(TIF)
Figure S2 Fit of the distribution of Hamming distances
with a Poisson model performed on the Envelope region,
specifically on partial E2 (932 nt). Each panel shows a
subject; the red line is the fit of the distribution of Hamming
distances (histogram) calculated from sequences derived from the
reconstruction of NGS data and from standard cloning. The poor
fit outcome for subject 23_Ch indicated the presence of more than
one founder virus. See also Table S3.
(TIF)
Figure S3 Evolutionary dynamics of HCV variants over
the E1/HVR1 region of the genome. Sequence analyses of
the two subjects who developed chronic infection, 240_Ch (A),
and 23_Ch (B) revealed the presence of selective sweeps. These
sweeps led to the emergence of new variants that replaced the
founder viruses (identified with an asterisk). Phylogenetic trees (left
panels) display nucleotide sequences of reconstructed haplotypes
derived from NGS data and clonal sequences. Names of each
sequence are labeled with a letter (H for haplotype and C for
clone), with the first number representing the sampling timepoint
and with the second number representing either the prevalence of
the haplotype or the clone number. Colors are also used to portray
the sampling timepoint (see legend). Infection dynamics for subject
240_Ch are consistent with a single founder, identified with the
most prevalent strain of cluster 240A (H2_0.65, indicated with an
asterisk), and with clones C2_6, and C2_17, and with the
consensus of the sequences from time-point 1. The pre-chronic
phase (corresponding with the color-coded time ranges 5 and 6) of
infection shows the emergence and dominance of a new subgroup
of viruses. 23_Ch has two founder viruses that successfully initiated
the infection (H1_0.25 and H1_0.27, indicated with an asterisk). A
new cluster emerged from the founder cluster and became
dominant in the pre-chronic phase. Trees are calculated using
Maximum Likelihood method (implemented in PhyML).
(TIF)
Figure S4 Evolutionary dynamics of HCV variants over
the partial NS3 region of the genome. Sequence analyses
(over 400 nt window) of the two subjects who developed chronic
infection, 240_Ch (panel A), and 23_Ch (panel B) revealed the
presence of selective sweeps. These sweeps led to the emergence of
new variants that replaced the founder virus(es). Phylogenetic trees
display nucleotide sequences of reconstructed haplotypes derived
from NGS data and clonal sequences. Names of each sequence are
labeled with a letter (H for haplotype), with the first number
representing the sampling timepoint and with the second number
representing the prevalence of the haplotype. Colors are also used
to portray the sampling timepoint (see legend).
(TIF)
Figure S5 Demographic reconstruction of the viral
populations. Demographic reconstruction from E1-HVR1 and
E2 sequences for subjects who cleared the infection (686_Cl and
360_Cl). In both subjects and in both genomic regions the
estimated effective population size (Nt, the product of the effective
population size and generation length in days) is higher than in
chronic subjects with peak around 10
4. Subject 686_Cl shows a
moderate increase in viral diversity over time, corroborating resuts
from Shannon entropy and Poisson-Fitter tests.
(TIF)
Table S1 Demographic and laboratory characteristics of the
subjects.
(DOC)
Table S2 Summary of the next generation sequencing (NGS)
data obtained for each subject.
(DOC)
Table S3 PoissonFitter test results for the single founder virus
analysis for each subject.
(DOC)
Table S4 Phenotypic analyses of the non-synonymous substitu-
tions over the course of the infection.
(XLS)
Table S5 Analysis of amino acid substitutions within predicted
HLA restricted cytotoxic T cell epitopes.
(DOC)
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(DOC)
Text S1 Haplotype reconstruction and method valida-
tion. Detailed information on the haplotype reconstruction from
NGS data. This methodology was validated with a 454 FLX run
performed in duplicate on four unique plasmids with known sites
of variation.
(DOC)
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